Product Brochure
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Appendix a Common Abbreviations Used in Medication
UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications. -
Sodium Selenate Hazard Summary Identification
Common Name: SODIUM SELENATE CAS Number: 13410-01-0 RTK Substance number: 1726 DOT Number: UN 2630 Date: November 2001 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY WORKPLACE EXPOSURE LIMITS * Sodium Selenate can affect you when breathed in and The following exposure limits are for Selenium compounds may be absorbed through the skin. (measured as Selenium): * Contact can irritate the skin and eyes. * Breathing Sodium Selenate can irritate the nose, throat OSHA: The legal airborne permissible exposure limit 3 and lungs causing coughing, wheezing and/or shortness of (PEL) is 0.2 mg/m averaged over an 8-hour breath. workshift. * High exposure can cause headache, nausea, vomiting, NIOSH: The recommended airborne exposure limit is coated tongue, metallic taste and garlic odor on the breath. 3 * Repeated exposure can cause pallor, nervousness and 0.2 mg/m averaged over a 10-hour workshift. mood changes. ACGIH: The recommended airborne exposure limit is * Sodium Selenate may damage the liver and kidneys and 3 affect the heart. 0.2 mg/m averaged over an 8-hour workshift. * The above exposure limits are for air levels only. When IDENTIFICATION skin contact also occurs, you may be overexposed, even Sodium Selenate is a white, sand-like solid. It is used as a though air levels are less than the limits listed above. medication and an insecticide. WAYS OF REDUCING EXPOSURE REASON FOR CITATION * Where possible, enclose operations and use local exhaust * Sodium Selenate is on the Hazardous Substance List ventilation at the site of chemical release. If local exhaust because it is regulated by OSHA and cited by ACGIH, ventilation or enclosure is not used, respirators should be DOT, NIOSH, DEP and EPA. -
Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats
BASIC RESEARCH www.jasn.org Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats Nancy S. Krieger,1 John R. Asplin,2 Ignacio Granja,2 Felix M. Ramos,1 Courtney Flotteron,1 Luojing Chen,1 Tong Tong Wu,3 Marc D. Grynpas,4 and David A. Bushinsky1 1Division of Nephrology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York; 2Litholink Corporation, Laboratory Corporation of America Holdings, Chicago, Illinois; 3Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, New York; and 4Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada ABSTRACT Background The pathophysiology of genetic hypercalciuric stone-forming rats parallels that of human idiopathic hypercalciuria. In this model, all animals form calcium phosphate stones. We previously found that chlorthalidone, but not potassium citrate, decreased stone formation in these rats. Methods To test whether chlorthalidone and potassium citrate combined would reduce calcium phos- phate stone formation more than either medication alone, four groups of rats were fed a fixed amount of a normal calcium and phosphorus diet, supplemented with potassium chloride (as control), potassium citrate, chlorthalidone (with potassium chloride to equalize potassium intake), or potassium citrate plus chlorthalidone. We measured urine every 6 weeks and assessed stone formation and bone quality at 18 weeks. Results Potassium citrate reduced urine calcium compared with controls, chlorthalidone reduced it fur- ther, and potassium citrate plus chlorthalidone reduced it even more. Chlorthalidone increased urine citrate and potassium citrate increased it even more; the combination did not increase it further. -
The Importance of Minerals in the Long Term Health of Humans Philip H
The Importance of Minerals in the Long Term Health of Humans Philip H. Merrell, PhD Technical Market Manager, Jost Chemical Co. Calcium 20 Ca 40.078 Copper 29 Cu 63.546 Iron Magnesium 26 12 Fe Mg 55.845 24.305 Manganese Zinc 25 30 Mn Zn 55.938 65.380 Table of Contents Introduction, Discussion and General Information ..................................1 Calcium ......................................................................................................3 Copper .......................................................................................................7 Iron ...........................................................................................................10 Magnesium ..............................................................................................13 Manganese ..............................................................................................16 Zinc ..........................................................................................................19 Introduction Daily intakes of several minerals are necessary for the continued basic functioning of the human body. The minerals, Calcium (Ca), Iron (Fe), Copper (Cu), Magnesium (Mg), Manganese (Mn), and Zinc (Zn) are known to be necessary for proper function and growth of the many systems in the human body and thus contribute to the overall health of the individual. There are several other trace minerals requirements. Minimum (and in some cases maximum) daily amounts for each of these minerals have been established by the Institute of -
Contact Allergy to Aluminium Siemund, Ingrid
Contact allergy to aluminium Siemund, Ingrid 2017 Document Version: Publisher's PDF, also known as Version of record Link to publication Citation for published version (APA): Siemund, I. (2017). Contact allergy to aluminium. Lund University: Faculty of Medicine. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 INGRID SIEMUND INGRID Contact allergy to aluminium Contact allergy to aluminium INGRID SIEMUND | DEPARTMENT OF OCCUPATIONAL AND ENVIRONMENTAL DERMATOLOGY | SKÅNE UNIVERSITY HOSPITAL, LUND UNIVERSITY 9 Department of Occupational and 789176 Environmental Dermatology Lund University, Faculty of Medicine 2017:113 Doctoral Dissertation Series 2017:113 194959 ISBN 978-91-7619-495-9 ISSN 1652-8220 Contact allergy to aluminium 1 2 Contact allergy to aluminium Ingrid Siemund DOCTORAL DISSERTATION by due permission of the Faculty of Medicine, Lund University, Sweden. -
Mgcl2 and Kcl Recovery from Brine Wastewater
University of Pennsylvania ScholarlyCommons Department of Chemical & Biomolecular Senior Design Reports (CBE) Engineering 4-2016 MgCl2 and KCl Recovery from Brine Wastewater Arthur M. Rempel University of Pennsylvania, [email protected] Kyra G. Berger University of Pennsylvania, [email protected] Elyssa A. Gensib University of Pennsylvania, [email protected] Aspen N. Walker University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/cbe_sdr Part of the Biochemical and Biomolecular Engineering Commons Rempel, Arthur M.; Berger, Kyra G.; Gensib, Elyssa A.; and Walker, Aspen N., "MgCl2 and KCl Recovery from Brine Wastewater" (2016). Senior Design Reports (CBE). 82. https://repository.upenn.edu/cbe_sdr/82 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/cbe_sdr/82 For more information, please contact [email protected]. MgCl2 and KCl Recovery from Brine Wastewater Abstract This project’s aim was to design an improved brine wastewater treatment system for desalination facilities. While a multitude of methods exist to do so, General Electric (GE)’s brine concentrator is leading the market by providing a method that not only treats the brine waste, but also recovers anywhere from 60- 94% of the water from the feed. However, their brine concentrator is relatively inefficient omfr both a financial and energetic perspective; our goal was to develop a system to match their results, while limiting costs and energy usage as best possible. We subsequently designed a system (referred to from here on out as the ‘MgCl2 Separation Unit’) to accomplish the aforementioned objectives. In addition to recovering pure water from concentrated brine, our process also recovers high purity MgCl2 and KCl crystals that are later sold to alleviate the overall process costs. -
List of Union Reference Dates A
Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov. -
United States Patent (19) 11 Patent Number: 5,253,711 Mondshine (45) Date of Patent: Oct
USOO525371 1A United States Patent (19) 11 Patent Number: 5,253,711 Mondshine (45) Date of Patent: Oct. 19, 1993 54) PROCESS FOR DECOMPOSING 2,268,215 12/1941 Kerr ...................................... 127/33 POLYSACCHARDES IN ALKALINE 3,167,510 /1965 Alter ..... sa as A8 a X8 a P. 252/8.551 3,655,644 4/1972 Durand ........................... 106/21 X AQUEOUS SYSTEMS 3,935,187 1/1976 Speakman ........................... 536/102 75 Inventor: Thomas C. Mondshine, Houston, 4,202,795 5/1980 Burnham et al. ............... 166/308 X Tex. 4,552,668 11/1985 Brown et al. ................... 166/300X Lachenal et al. ..................... 162/25 Assignee: Texas United Chemical Corp., 4,787,959 11/1988 (73) Primary Examiner-George A. Suchfield Houston, Tex. Attorney, Agent, or Firm-Roy F. House 21 Appl. No.: 844,167 57 ABSTRACT 22 Filed: Mar. 2, 1992 Alkaline earth metal or transition metal peroxides are (51) int. Cli.............................................. E21B 43/26 used as a delayed breaker in alkaline aqueous fluids 52) U.S. C. .................................... 166/300; 166/308; containing a water soluble hydrophilic polysaccharide 252/8.551; 252/326 polymer hydrated therein. The peroxide is activated by (58) Field of Search ............................... 166/300, 308; increasing the temperature of the fluid. The invention is 252/8.551, 326,358; 536/41, 80, 88 particularly useful for the delayed break of hydraulic 56) References Cited fracturing fluids containing hydroxypropyl guar poly c. U.S. PATENT DOCUMENTS i,953,398 4/1934 Eskew ................................... 536/41 10 Claims, No Drawings 5,253,711 1. 2 G. W. Hawkins, and H. D. Brannon, Feb. -
Magnesium Magic by Terri Saunders
Magnesium Magic By Terri Saunders Minerals provide the physical elements that comprise life and fats and amino acids and create the physical structure of the of all the minerals on Earth, none are as essential to life as the body based on the genetic blueprint provided by the RNA and element magnesium. The Chinese word for magnesium is DNA. “mei” meaning beautiful mineral, and traditional Chinese Magnesium does an intricate dance with calcium to regulate healers consider it to be paramount in healing properties due to significant body functions. Magnesium plays a critical role in its ability to prevent and cure disease, maintain health and the function of the nervous system by acting as a gatekeeper for promote longevity. Dr. Jerry Aikawa refers to magnesium as calcium, permitting just enough calcium to enter a nerve cell to the most important mineral to man and all other living allow electrical transmission along the nerves to and from the organisms. brain, then forcing the calcium back out again. This exchange Deposits of magnesium were discovered by man near the provides the electrical spark that powers our thoughts and ancient Greek city of Magnesia. Magnesium sulfate (Epsom emotions. While calcium contracts muscle fibers, magnesium salts) was employed then as a laxative and still is today. relaxes muscles. When there is too much calcium and Magnesium was also used to heal a variety of conditions insufficient magnesium inside a cell the muscles stay contracted including heartburn, depression, vertigo, ulcers, kidney stones, resulting in spasms, twitches and even convulsions. jaundice, gout and worms. In the last 40 years, over 1,000 There are many smooth muscles in the body that can over- laboratory studies have been conducted revealing at least a contract and go into spasm when magnesium is deficient. -
Using Sodium and Potassium Bicarbonates in the Prevention and Treatment of All Sickness and Disease
International Journal of Complementary & Alternative Medicine Using Sodium and Potassium Bicarbonates in the Prevention and Treatment of all Sickness and Disease Abstract Mini Review This article suggests that the use sodium and potassium bicarbonates are non- Volume 9 Issue 6 - 2017 toxic primary alkalizing agents in the prevention and treatment of all cancers, kidney disease, liver disease, Type I & Type II diabetes, Lupus, heart disease, Pharmacological toxicosis, vascular surgery operation, tonsillar herniation due Universal Medical Imaging Group, USA to cerebral edema, lactic acid toxicosis, and hyponatremia or low salt or loss of salts due to excessive or over-exercise! *Corresponding author: Robert O Young, Universal Medical Imaging Group, 16390 Dia Del Sol Valley Center, California Keywords: Cancer; Diabetes; Lupus; Heart disease; Vascular surgery; 92082, USA, Tel: 760 751 8321; Herniation; Cerebral edema; Lactic acid toxicosis; Liver disease; Kidney disease; Email: Hyponatremia; Pharmacological toxicosis Received: January 10, 2016 | Published: December 08, 2017 Introduction Sodium and potassium bicarbonate increases the hydroxyl ions or electron levels through increased alkalinity to the cells Sodium and potassium bicarbonate are excellent agents for buffering the metabolic acids that can cause cancer [20]. It is a natural alkaline approach in the treatment for all sickness and also one of the most basic medicines in allopathic and alternative disease, including cancer. Sodium bicarbonate is the universal medicine we have for the treatment of kidney disease. Research by mainstream treatment of acidosis. It is used every day by British scientists at the Royal London Hospital shows that sodium oncologists to neutralize the heavy acidic nature of their chemical bicarbonate can dramatically slow the progress of chronic kidney and chemotherapeutic agents which are often quite toxic. -
Food and Drug Administration, HHS § 184.1639
Food and Drug Administration, HHS § 184.1639 (2) The ingredient is used in food at Academy Press, 2101 Constitution Ave. levels not to exceed current good man- NW., Washington, DC 20418, or may be ufacturing practice. examined at the National Archives and (d) Prior sanctions for this ingredient Records Administration (NARA). For different from the uses established in information on the availability of this this section do not exist or have been material at NARA, call 202–741–6030, or waived. go to: http://www.archives.gov/ federallregister/ [48 FR 52444, Nov. 18, 1983] codeloflfederallregulations/ § 184.1634 Potassium iodide. ibrllocations.html. (c) The ingredient is used as a dough (a) Potassium iodide (KI, CAS Reg. strengthener as defined in § 170.3(o)(6) No. 7681–11–0) is the potassium salt of of this chapter. hydriodic acid. It occurs naturally in (d) The ingredient is used in the man- sea water and in salt deposits, but can ufacture of bread in accordance with be prepared by reacting hydriodic acid § 184.1(b)(2) of this chapter in an (HI) with potassium bicarbonate amount not to exceed 0.0075 percent (KHCO ). 3 based on the weight of the flour. (b) The ingredient meets the speci- (e) Prior sanctions for this ingredient fications of the ‘‘Food Chemicals different from the uses established in Codex,’’ 3d Ed. (1981), pp. 246–247, which this section do not exist or have been is incorporated by reference. Copies waived. may be obtained from the National Academy Press, 2101 Constitution Ave. [43 FR 11699, Mar. 21, 1978, as amended at 49 NW., Washington, DC 20418, or may be FR 5613, Feb. -
Some Drugs Are Excluded from Medicare Part D, but Are Covered by Your Medicaid Benefits Under the Healthpartners® MSHO Plan (HMO)
Some drugs are excluded from Medicare Part D, but are covered by your Medicaid benefits under the HealthPartners® MSHO Plan (HMO). These drugs include some over‐the‐counter (OTC) items, vitamins, and cough and cold medicines. If covered, these drugs will have no copay and will not count toward your total drug cost. For questions, please call Member Services at 952‐967‐7029 or 1‐888‐820‐4285. TTY members should call 952‐883‐6060 or 1‐800‐443‐0156. From October 1 through February 14, we take calls from 8 a.m. to 8 p.m., seven days a week. You’ll speak with a representative. From February 15 to September 30, call us 8 a.m. to 8 p.m. Monday through Friday to speak with a representative. On Saturdays, Sundays and holidays, you can leave a message and we’ll get back to you within one business day. Drug Description Strength 3 DAY VAGINAL 4% 5‐HYDROXYTRYPTOPHAN 50 MG ABSORBASE ACETAMINOPHEN 500 MG ACETAMINOPHEN 120MG ACETAMINOPHEN 325 MG ACETAMINOPHEN 650MG ACETAMINOPHEN 80 MG ACETAMINOPHEN 650 MG ACETAMINOPHEN 160 MG/5ML ACETAMINOPHEN 500 MG/5ML ACETAMINOPHEN 160 MG/5ML ACETAMINOPHEN 500MG/15ML ACETAMINOPHEN 100 MG/ML ACETAMINOPHEN 500 MG ACETAMINOPHEN 325 MG ACETAMINOPHEN 500 MG ACETAMINOPHEN 80 MG ACETAMINOPHEN 100.00% ACETAMINOPHEN 80 MG ACETAMINOPHEN 160 MG ACETAMINOPHEN 80MG/0.8ML ACETAMINOPHEN‐BUTALBITAL 50MG‐325MG ACNE CLEANSING PADS 2% ACNE TREATMENT,EXTRA STRENGTH 10% ACT ANTI‐CAVITY MOUTH RINSE 0.05% Updated 12/01/2012 ACTICAL ACTIDOSE‐AQUA 50G/240ML ACTIDOSE‐AQUA 15G/72ML ACTIDOSE‐AQUA 25G/120ML ACTIVATED CHARCOAL 25 G ADEKS 7.5 MG